Rat myoblasts were genetically modified to express tyrosine hydroxylase (TH) and produce dopamine in culture. Implanting TH gene-transfected myoblasts into the denervated striatum of 6-OHDA-lesioned rats significantly decreased rotational asymmetry by 50 to approximately 60%. Improvement persisted for up to 13 months. Genetically modified cells could survive and express transgene in the striatum as demonstrated by RT-PCR and immunohisto-
Parkinson's disease (PD) is a progressive brain disorder that disrupts normal motor functions. Deterioration of movement has been linked with the degeneration of dopamine (DA) neurons in the substantia nigra pars compacta. Oral administration of the DA precursor leveodopa (L-dopa) is the current mainstay of treatment and initially is clearly effective. However, the effect gradually diminishes as the disease progresses. In view of the significant morbidity and mortality associated with advanced, drug-refractory PD, alternative therapeutic strategies have been explored, including stimulation of brain pathways to bypass the damage, 1 additional damage to remaining disinhibited circuits, 2 as well as cell and gene therapy. 3 Both cell and gene therapy are based on the concept of local replacement of DA or precursor in the corpus striatum which is the target of terminals containing DA. Autologous adrenal chromaffin cells were the first cells to be tested clinically, however, survival of the grafts are poor and clinical experiments have virtually ceased. Grafts of freshly dissected fetal substantia nigra containing DA neurons have shown promising long-term effect in some PD patients. However, the use of fetal tissue is limited by ethical and legal problems, tissue availability, survivability and some inherent biological problems. 4 In an effort to establish another source of DA-producing cells, immortalized cells, both spontaneously and genetically engineered, including TH-producing fibroblasts, 5 DA-producing SV40 large T antigen- induced transformed cells 6, 7 and multipotent neural cells [8] [9] [10] have been established. The grafting of these cells in animal models of PD has demonstrated variable improvements in neurological deficits. In this study we demonstrate the efficacy of tyrosine hydroxylase (TH) gene-transfected myoblasts in ameliorating some of the neurodeficits in a hemiparkinsonism rodent model. TH, the rate limiting enzyme in dopa biosynthesis process, was used as the therapeutic gene for two reasons: (1) the great majority of DA neurons are damaged in the advanced patient and (2) over 90% of the DA neurons are destroyed in the rat model used in this study. 11 Therefore, replacement with TH-producing cells may improve the symptoms in advanced cases more effectively than other potential candidate genes such as neurotrophin.
The myoblast line L6-TG stably transfected with the TH gene (named as L6-TG-TH) was selected and analyzed for exogenous TH integration and expression. Total cellular DNA was isolated from L6-TG-TH and L6-TG, respectively. The coding sequence of TH was amplified by PCR using specific primers complementary to both terminal sequences of TH coding sequence. A 1.5 kb product was observed in DNA from L6-TG-TH (Figure 1 , lane 3) but not in nontransfected cells ( Figure 1, lane 2) . This 1.5 kb TH fragment was amplified from the integrated exogenous TH cDNA since the endogenous TH gene includes 12 introns and is 8 kb long.
Expression of TH in transfected cells was demonstrated by immunohistochemical staining. L6-TG-TH exhibited brown color (Figure 2 ) while parental L6-TG was negative (data not shown). Positive cells showed different staining intensity possibly due to the difference in the expression of exogenous gene.
The bioactivity of TH expressed in transfected cells was examined by the SPG method. Green cells were observed under a fluorescence microscope in L6-TG-TH ( Figure 3 ) but not in nontransfected L6-TG. Furthermore, 3.57 g DA was detected in the cell extract of 1 × 10 6 LG-TG-TH cells by HPLC but no detectable DA was found in L6-TG. This indicates that myoblasts might become a more attractive carrier than fibroblasts for ex vivo gene therapy of PD since DA can be produced in transgenic myoblasts. Therefore, the production of DA would not be restricted by endogenous activity of decarboxylase in the host striatum which has been reported to be reduced in PD patients. 12 A hemiparkinsonism rodent model unilaterally lesioned with 6-hydroxydopamine (6-OHDA) was used to demonstrate the therapeutic efficacy of TH gene-transfected myoblasts. Transplantation of LC-TG-TH (2.5 × 10 5 cells per rat) significantly improved the apomorphineinduced rotation behavior of PD rats. Two weeks after transplantation, rotation of the gene therapy group receiving L6-TG-TH suspension was reduced by 59.4% compared with the pre-treatment counts. All the rats in this group exhibited improvement of rotation and the significant improvement persisted for up to 56 weeks (P Ͻ 0.01, Figure 4 ). The mean of the decrease was 52.6% during the 13 month study period. Spontaneous recovery did not occur in the 6-OHDA-induced rodent model used in the study indicating the irreversible lesion and complete destruction of DA neurons in this animal model. Grafts of nontransfected, parental cells did not produce any recovery in behavior (P Ͼ 0.05) indicating that the decrease of rotation in the gene therapy group is due to expression of exogenous TH in transgenic cells. The significant improvement of rotation behavior persisted for up to 13 months after transplantation whereas most ex vivo gene therapy studies to date have reported not more than 6 months. 5, 6, [13] [14] [15] TH expression was demonstrated on mRNA and protein level by RT-PCR and immunohistochemistry. A TH fragment of 513 bp was only detected in striatum receiving L6-TG-TH ( Figure 5 , lane 2) whereas neither the nondenervated striatum of the gene therapy group nor the striatum of the control group exhibited any fragments ( Figure 5, lanes 3 and 4) . Amplification was not apparent either in the negative control or without the addition of reverse transcriptase ( Figure 5, lanes 6, 7 and 8 ), suggesting that the TH fragment observed in the L6-TG-THinjected striatum was not derived from contaminated DNA.
Immunohistochemistry was performed at 1, 3 and 5 months respectively after transplantation. Positive cells Gene Therapy were observed in the vicinity of the injection tract in the L6-TG-TH-transplanted striata ( Figure 6 ). Some separated cells at a distance from the injection tract also stained brown. In contrast, no TH-positive cells were observed in either nondenervated striata of the gene therapy group or both sides of the striata of the control group.
The contents of DA and its metabolites in striatum tissues were measured by HPLC-ECD 6 months after transplantation (Figure 7) . Compared with the nondenervated striatum, DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) contents in the L6-TG-injected striatum of the control group were reduced to 1.94%, 2.74% and 1.43%, respectively (P Ͻ 0.01). However, DOPAC and HVA contents in the L6-TG-TH-injected striatum were increased to 117% and 87.85% compared with the nondenervated striatum (P Ͼ 0.05) after gene therapy. The DA content was increased to 49.99% of normal level and was 25-fold higher than that in the control group (P Ͻ 0.01), indicating the significant therapeutic efficacy of TH genetransfected myoblasts.
In summary, we carried out serial analyses to demonstrate the performance and efficacy of the TH gene-transfected myoblast line in PD rats including RT-PCR for gene expression, immunohistochemistry for TH, HPLC for the level of DA and its metabolites and behavioral tests. Although a previous study by others using primary myoblasts and myotube was later retracted, 16 long-term phenotype improvement was observed in our study. This is probably due to the fact that we used the stably transfected myoblast line.
In general, immortalized cell lines are easy to manipulate genetically and can be highly standardized and produced in unlimited numbers so that they are used in first attempts in ex vivo gene therapy. However, a major concern is the practical use of immortalized cells because of the potential danger of malignant transformation of grafted cells. Our present observations show that grafting of TH gene-transfected L6-TG cells does not result in tumors as late as 13 months after transplantation. No apparent proliferation of grafted cells was observed (data not shown) suggesting that such cells may be grafted into the brain without significant danger of tumor formation.
Another major concern is the issue of graft rejection. Our present observations show no evidence of inflammatory response elicited by grafts of transfected or nontransfected L6-TG cells in the immunocompetent rats without immunosuppression. This observation is consistent with other results, 5, 17 and may be due to the fact that the brain is an immunoprivileged organ 18 and L6-TG cells are free of donor antigen-presenting cells which are primarily responsible for the induction of alloimmunization. 19 The results observed in rat models demonstrate that TH gene-transfected L6-TG are neither tumorigenic nor immunogenic. They may serve as an unlimited, ready-touse source of nonautologous cells for transplant therapy.
The next reasonable step is to investigate the efficacy of genetically modified cells in nonhuman primates. In our preliminary pilot study of xenotransplantation, two rhesus monkeys receiving microencapsulated TH genetransfected myoblasts exhibited significant behavior improvement (data not shown). Alginate microcapsules were used to prevent immune rejection because they have many desirable properties such as biocompatibility, permeability to the exit of the biological product but not the entry of immune mediators. 20 No obvious rejection was observed in this study. Ongoing studies will assess the long-term efficacy and safety of this approach.
Compared with the constitutive production of DA in transfected non-neural cells, the use of neural cells may be advantageous since they have the potential to send out neurites and form synapses with adjacent target neurons. They also have the potential of being regulated in vivo. Nerve cells, as 'communicating' cells, would seem to be the best replacement for degenerating neurons. However, the difficulties in obtaining, culturing and gene manipulating hinder their application in ex vivo gene therapy. Recently great progress has been made in isolation and in vitro proliferation of progenitor cells derived from the central nervous system. 8, 21, 22 Such cells may turn out to be ideal gene carriers for gene transfer. Another alternative is direct in situ gene transfer with lipofection 23, 24 or viral vectors. [25] [26] [27] [28] However, it is more difficult to transfer genes to nondividing neurons. Also the inherent toxicity of current generation HSV, adenovirus or HIV-derived vectors has to be considered. To date, little data have shown the long-term effect of in vivo gene therapy in PD. We suppose that an in vivo strategy might be useful in early stage PD because there are substantial numbers of neurons remaining which could be targets for viral vectors. Degeneration of neurons might be prevented by expression of neurotrophins. Conversely, following severe loss of nigra cell bodies and synaptic contacts, it is less likely that recombinant viruses alone could restore the appropriate release of DA, and in such advanced cases, grafts of neural cells or TH-producing cells may be more appropriate therapy. Both approaches are being investigated in our laboratory.
